Provided by:
Melanoma and Cutaneous Malignancy
Tumor Board
2015
Melanoma and Cutaneous Malignancy Tumor Board
10/29/2015
2:00-3:00pm
PCAM2 West Conference Room
Moderators: Dr. Lynn Schuchter and Dr. Giorgos Karakousis
Target Audience
This program has been designed for departmental/institutional faculty, fellows, residents, medical students, other
health sciences students, nurses, and allied health professionals in the medical specialties of medical oncology, surgery,
dermatology, dermatopathology, ENT, pathology, radiology, and radiation oncology.
Educational Objectives
After completing this activity, participants should be able to:
 Provide a multidisciplinary approach to care for melanoma patients
 Develop a plan for accurate diagnosis, complete staging, and treatment for patients with melanoma and other
cutaneous malignancies
 Treat and manage patients with melanoma and other cutaneous malignancies
 Describe available clinical trials to patients and help propose and develop clinical trials for particular patient
populations where there is a need
Accreditation
The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 1 AMA
PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in
the activity.
Acknowledgement of Commercial Support*
NONE
For more information, please contact
Shannon Harmon
215-662-6383
Shannon.harmon@uphs.upenn.edu
Check your CME online at www.penncmeonline.com
Disclosure of Relevant Financial Relationships and Unapproved Uses of Products
It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to
control the content of an educational activity to disclose to the learners all relevant financial relationships that they have
with any commercial interest that provides products or services that may be relevant to the content of this continuing
medical education activity. For this purpose we consider relationships of the person involved in the CME activity to
include financial relationships of a spouse or partner.
The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from
involvement in CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in
improving medical practice, are based on valid content, and are independent of control from commercial interests and
free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure
information provided to the Penn Office of CME was found to contain relationships that created a conflict of interest
relative to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically
rigorous and evidence-based presentations.
The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania, Mila Kostic,
Director of CME and the peer reviewer Zalman Agus, MD, have disclosed that they have no relevant financial
relationships with any commercial interests related to the content of this educational activity.
The following individuals have disclosed that they have no relevant financial relationships with any commercial interests
related to the content of this educational activity:
PLANNING COMMITTEE MEMBER & PRESENTER NAME
LYNN SCHUCHTER, MD
PRESENTER NAME
PETER AHN, MD
MICHAEL FARWELL, MD
HAYLEY MILLER, CRNP
EMILY CHU, MD, PHD
TARA GANGADHAR, MD
JAGRUTI SHAH, MD
SHANNON HARMON, BS
MARK DIAMOND, MD, PHD
KRISTIN KREIDER, PA-C
XIAOWEI XU, MD, PHD
DAVID ELDER, MB, CHB
CHRISTOPHER MILLER, MD
The following individuals have reported the listed relevant financial relationships with commercial interests related to
the content of this educational activity.
PLANNING COMMITTEE & PRESENTER NAME
NAME OF COMMERCIAL INTEREST
RELATIONSHIP
Giorgos Karakousis, MD
Amgen and Castle Biosciences
Advisory Board
PRESENTER NAME
NAME OF COMMERCIAL INTEREST
RELATIONSHIP
RAVI AMARAVADI, MD
PRESAGE BIOSCIENCES & SPRINT BIOSCIENCES
CONSULTANT
JACOB DUBROFF, MD, PHD
GE HEALTHCARE
RESEARCH
ROSALIE ELENITSAS, MD
MYRIAD GENETICS
CONSULTANT
DAVID MANKOFF, MD, PHD
REFLEXION CORP
SCIENTIFIC BOARD
GE HEALTHCARE
ADVISORY BOARD
Relevant Financial Relationships: Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty,
intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding
diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position,
independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels,
board membership, and other activities from which remuneration is received or expected
DISCLOSURE OF UNAPPROVED USES OF PRODUCTS
PRESENTER NAME
RAVI AMARAVADI, MD
PRODUCT
HYDROXYCHLOROQUINE
INVESTIGATIONAL AND/OR OFF-LABEL USE
CANCER THERAPY-TOPIC OF ONGOING RESEARCH